Araştırma Makalesi
BibTex RIS Kaynak Göster

Retrospective evaluation of malignant melanoma patients: A single-center experience

Yıl 2021, Cilt: 6 Sayı: 2, 98 - 104, 05.05.2021

Mustafa Solak , Saadettin Kılıçkap , İsmail Celık

https://doi.org/10.22391/fppc.717911

Öz

Introduction: Melanoma is a cancer arising from the malignant transformation of melanocytes. It is mostly seen in the skin, eyes, mucosal membranes, and meninges. Melanoma is one of the fastest rising of all cancers in the world.

Methods: We retrospectively examined the medical records of adult patients who were diagnosed with melanoma between January 2005 and December 2013 according to the Hospital-Based Cancer Registry (HBCR) of Hacettepe University Oncology Hospital.

Results: A total of 338 patients [193 (57.1%) men and 145 (42.9%) women] were included in the study. The male to female ratio was 1.3/1. The mean age of patients was 55.2±15.2 years (minimum-maximum: 16-87 years). The rate of male patients was higher in patients with cutaneous and uveal melanoma (respectively, 56.8% and 58.6%), whereas the rate of female patients was higher in patients with mucosal melanoma (female: 55.6% and male: 44.4%; respectively, p=0.746 and p=0.518). The median follow-up time was estimated to be 27.7 months (1-103 months). During follow-up period, 127 (37.6%) patients died, and 16 (4.7%) patients were lost to follow-up. The median overall survival time was 76.3 months. The 5-year survival rate was 53%. When all patients were evaluated according to melanoma subtypes, patients with melanoma of unknown primary origin had the lowest median survival time (6.4 months).

Conclusions: It is necessary to increase the awareness of people about melanoma and to make physicians more sensitive about skin examination in order to detect cutaneous melanomas in the early stages.

Anahtar Kelimeler

Melanoma demographic factors pathology survival

Kaynakça

  • 1. Lang P, Maize J, Rigel D, Friedman R, Dzubow L. Cancer of the skin. 2005.
  • 2. Brochez L, Naeyaert J. Understanding the trends in melanoma incidence and mortality: where do we stand? Eur J Dermatol. 2000; 10 (1):71-5. https://doi.org/10.1684/ejd.2020.3698
  • 3. Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer. 2010; 46 (2):270-83. https://doi.org/10.1016/j.ejca.2009.10.032
  • 4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA: a cancer journal for clinicians. 2009;59 (4):225-49. https://doi.org/10.3322/caac.20006
  • 5. Ries LA, Harkins D, Krapcho M, Mariotto A, Miller B, Feuer EJ, et al. SEER cancer statistics review, 1975-2003. 2006.
  • 6. [Cancer Statistics Turkey, 2016] (in Turkish) Republic of Turkey Ministry of Health, Department of Cancer. Available at: https://hsgm.saglik.gov.tr/depo/birimler/kanser-db/istatistik/Trkiye_Kanser_statistikleri_2016.pdf. (Access Date: January 21, 2021)
  • 7. Tas F, Kurul S, Camlica H, Topuz E. Malignant melanoma in Turkey: a single institution's experience on 475 cases. Jpn J Clin Oncol. 2006;36 (12):794-9. https://doi.org/10.1093/jjco/hyl114
  • 8. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer: Interdisciplinary International Journal of the American Cancer Society. 1998;83 (8):1664-78. https://doi.org/10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G
  • 9. Tas F, Keskin S, Karadeniz A, Dagoglu N, Sen F, Kilic L, et al. Noncutaneous melanoma have distinct features from each other and cutaneous melanoma. Oncology. 2011;81 (5-6):353-8. https://doi.org/10.1159/000334863
  • 10. McGovern VJ, Mihm Jr MC, Bailly C, Booth JC, Clark Jr WH, Cochran AJ, et al. The classification of malignant melanoma and its histologic reporting. Cancer. 1973;32 (6):1446-57. https://doi.org/10.1002/1097-0142(197312)32:6<1446::AID-CNCR2820320623>3.0.CO;2-8
  • 11. Giles G, Staples M, McCredie M, Coates M. Multiple primary melanomas: an analysis of cancer registry data from Victoria and New South Wales. Melanoma research. 1995;5 (6):433-8. https://www.ncbi.nlm.nih.gov/pubmed/8589618
  • 12. Langley RG, Sober AJ. Clinical recognition of melanoma and its precursors. Hematol Oncol Clin N Am. 1998;12 (4):699-715. https://doi.org/10.1016/S0889-8588(05)70019-8
  • 13. Weinstock M, Sober A. The risk of progression of lentigo maligna to lentigo maligna melanoma. British Journal of Dermatology. 1987;116 (3):303-10. https://doi.org/10.1111/j.1365-2133.1987.tb05843.x
  • 14. Clark Jr WH, Mihm Jr MC. Lentigo maligna and lentigo-maligna melanoma. The American journal of pathology. 1969;55 (1):39. https://www.ncbi.nlm.nih.gov/pubmed/5776171
  • 15. Balch C, Karakousis C, Mettlin C, Natarajan N, Donegan W, Smart C, et al. Management of cutaneous melanoma in the United States. Surgery, gynecology & obstetrics. 1984;158 (4):311-8. https://www.ncbi.nlm.nih.gov/pubmed/6710291
  • 16. Balch CM, Gershenwald JE, Soong S-j, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27 (36):6199. https://doi.org/10.1200/JCO.2009.23.4799
  • 17. Bell DJ, Wilson MW. Choroidal melanoma: natural history and management options. Cancer Control. 2004;11 (5):296-303. https://doi.org/10.1177/107327480401100503
  • 18. Shields CL, Shields JA. Recent developments in the management of choroidal melanoma. Curr Opin Ophthalmol. 2004;15 (3):244-51. https://doi.org/10.1097/01.icu.0000120713.35941.e4
  • 19. Lee YTN. Malignant melanoma: pattern of metastasis. CA: a cancer journal for clinicians. 1980;30 (3):137-42. https://doi.org/10.3322/canjclin.30.3.137
  • 20. Piotrowski W, Brock M, Klinger M. CNS Metastases Neurosurgery in the Aged: Proceedings of the 34th Annual Meeting of the Deutsche Gesellschaft für Neurochirurgie, Mannheim, April 27-30, 1983: Springer Science & Business Media; 2012. https://doi.org/10.1007/978-3-642-69360-1
  • 21. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10 (5):1670-7. https://doi.org/10.1158/1078-0432.CCR-1103-3
  • 22. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncology. 1999;17 (9):2745. https://doi.org/10.1200/JCO.1999.17.9.2745
  • 23. Avril MF, Aamdal S, Grob J, Hauschild A, Mohr P, Bonerandi J, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncology. 2004;22 (6):1118-25. https://doi.org/10.1200/JCO.2004.04.165
  • 24. Glover D, Glick JH, Weiler C, Fox K, Guerry D. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncology. 1987;5 (4):574-8. https://doi.org/10.1200/JCO.1987.5.4.574
  • 25. Quagliana JM, Stephens R, Baker L, Costanzi J. Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study. J Clin Oncology. 1984;2 (4):316-9. https://doi.org/10.1200/JCO.1984.2.4.316
  • 26. Aamdal S, Wolff I, Kaplan S, Paridaens R, Kerger J, Schachter J, et al. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer. 1994;30 (8):1061-4. https://doi.org/10.1016/0959-8049(94)90456-1
  • 27. Dhomen N, Marais R. New insight into BRAF mutations in cancer. Current opinion in genetics & development. 2007;17 (1):31-9. https://doi.org/10.1016/j.gde.2006.12.005
  • 28. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364 (26):2507-16. https://doi.org/10.1056/NEJMoa1103782
  • 29. [Cancer Statistics Turkey, 2008] (in Turkish). Republic of Turkey Ministry of Health, Department of Cancer. Available at: https://hsgm.saglik.gov.tr/depo/birimler/kanser-db/istatistik/2009kanseraporu-1.pdf (Access Date: March 01, 2015)
  • 30. Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int. J. Cancer. 1997;73 (2):198-203. https://doi.org/10.1002/(SICI)1097-0215(19971009)73:2<198::AID-IJC6>3.0.CO;2-R
  • 31. Nelemans PJ, Groenendal H, Kiemeney L, Rampen F, Ruiter DJ, Verbeek A. Effect of intermittent exposure to sunlight on melanoma risk among indoor workers and sun-sensitive individuals. Environmental health perspectives. 1993;101 (3):252. https://doi.org/10.1289/ehp.93101252
  • 32. The International Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: a systematic review. Int. J. Cance. 2007;120 (5):1116-22. https://doi.org/10.1002/ijc.22453

Malign melanom hastalarının retrospektif değerlendirilmesi: Tek merkezli bir deneyim

Yıl 2021, Cilt: 6 Sayı: 2, 98 - 104, 05.05.2021

Mustafa Solak , Saadettin Kılıçkap , İsmail Celık

https://doi.org/10.22391/fppc.717911

Öz

Giriş: Melanom, normal melanositlerin malign transformasyonu ile oluşan bir kanserdir. En fazla ciltte olmak üzere gözde, mukozalarda ve meninkslerde görülmektedir. Melanom tüm kanserler arasında sıklığı en fazla artan kanser türüdür.

Yöntem: Hacettepe Üniversitesi Onkoloji Hastanesi'nin, Hastaneye Dayalı Kanser Kayıt Merkezine göre Ocak 2005- Aralık 2013 tarihleri arasında melanom tanısı alan yetişkin hastaların tıbbi kayıtlarını retrospektif olarak inceledik.

Bulgular: Çalışmaya 193’ü (%57,1) erkek ve 145’i (%42,9) kadın olmak üzere toplam 338 hasta alındı. Çalışmaya alınan hastaların, erkek/ kadın oranı 1.3/1 olarak bulundu. Hastaların yaş ortalaması 55.2±15.2 idi (minimum ve maksimum: 16-87 yaş). Cilt ve uveal melanomlu hastalarda erkek cinsiyet daha fazla sıklıkta iken (%56,8 ve %58,6), mukozal melanomlu hastalar arasında kadın cinsiyetin daha baskın olduğu bulundu (kadın: %55,6, erkek %44,4; sırasıyla p=0.746ve p=0.518). Çalışmaya alınan hastalarda ortanca izlem süresi 27,7 ay (1-103 ay) olarak saptandı. Bu süre içinde hastaların 127’si (%37,6) kaybedildi, 16 hasta (%4,7) ise izlem-dışı kaldı. Ortanca genel sağkalım süresi tüm melanomlu hastalar için 76,3 ay iken, 5 yıllık sağkalım süresi %53 olarak bulundu. Melanom tipine göre ayrı ayrı hastalar değerlendirildiğinde, kökeni bilinmeyen melanomlu olgularda ortanca sağkalım en kötü idi (6,4 ay).

Sonuç: Kişilerin melanom konusunda farkındalıklarının artırılması ve hekimlerin cilt muayenesi konusunda daha duyarlı hale getirilmesi, kütanöz melanomların erken evrelerde tespit edilebilmesi için gereklidir.

Anahtar Kelimeler

Melanom demografik faktörler patoloji sağkalım

Kaynakça

  • 1. Lang P, Maize J, Rigel D, Friedman R, Dzubow L. Cancer of the skin. 2005.
  • 2. Brochez L, Naeyaert J. Understanding the trends in melanoma incidence and mortality: where do we stand? Eur J Dermatol. 2000; 10 (1):71-5. https://doi.org/10.1684/ejd.2020.3698
  • 3. Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer. 2010; 46 (2):270-83. https://doi.org/10.1016/j.ejca.2009.10.032
  • 4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA: a cancer journal for clinicians. 2009;59 (4):225-49. https://doi.org/10.3322/caac.20006
  • 5. Ries LA, Harkins D, Krapcho M, Mariotto A, Miller B, Feuer EJ, et al. SEER cancer statistics review, 1975-2003. 2006.
  • 6. [Cancer Statistics Turkey, 2016] (in Turkish) Republic of Turkey Ministry of Health, Department of Cancer. Available at: https://hsgm.saglik.gov.tr/depo/birimler/kanser-db/istatistik/Trkiye_Kanser_statistikleri_2016.pdf. (Access Date: January 21, 2021)
  • 7. Tas F, Kurul S, Camlica H, Topuz E. Malignant melanoma in Turkey: a single institution's experience on 475 cases. Jpn J Clin Oncol. 2006;36 (12):794-9. https://doi.org/10.1093/jjco/hyl114
  • 8. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer: Interdisciplinary International Journal of the American Cancer Society. 1998;83 (8):1664-78. https://doi.org/10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G
  • 9. Tas F, Keskin S, Karadeniz A, Dagoglu N, Sen F, Kilic L, et al. Noncutaneous melanoma have distinct features from each other and cutaneous melanoma. Oncology. 2011;81 (5-6):353-8. https://doi.org/10.1159/000334863
  • 10. McGovern VJ, Mihm Jr MC, Bailly C, Booth JC, Clark Jr WH, Cochran AJ, et al. The classification of malignant melanoma and its histologic reporting. Cancer. 1973;32 (6):1446-57. https://doi.org/10.1002/1097-0142(197312)32:6<1446::AID-CNCR2820320623>3.0.CO;2-8
  • 11. Giles G, Staples M, McCredie M, Coates M. Multiple primary melanomas: an analysis of cancer registry data from Victoria and New South Wales. Melanoma research. 1995;5 (6):433-8. https://www.ncbi.nlm.nih.gov/pubmed/8589618
  • 12. Langley RG, Sober AJ. Clinical recognition of melanoma and its precursors. Hematol Oncol Clin N Am. 1998;12 (4):699-715. https://doi.org/10.1016/S0889-8588(05)70019-8
  • 13. Weinstock M, Sober A. The risk of progression of lentigo maligna to lentigo maligna melanoma. British Journal of Dermatology. 1987;116 (3):303-10. https://doi.org/10.1111/j.1365-2133.1987.tb05843.x
  • 14. Clark Jr WH, Mihm Jr MC. Lentigo maligna and lentigo-maligna melanoma. The American journal of pathology. 1969;55 (1):39. https://www.ncbi.nlm.nih.gov/pubmed/5776171
  • 15. Balch C, Karakousis C, Mettlin C, Natarajan N, Donegan W, Smart C, et al. Management of cutaneous melanoma in the United States. Surgery, gynecology & obstetrics. 1984;158 (4):311-8. https://www.ncbi.nlm.nih.gov/pubmed/6710291
  • 16. Balch CM, Gershenwald JE, Soong S-j, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27 (36):6199. https://doi.org/10.1200/JCO.2009.23.4799
  • 17. Bell DJ, Wilson MW. Choroidal melanoma: natural history and management options. Cancer Control. 2004;11 (5):296-303. https://doi.org/10.1177/107327480401100503
  • 18. Shields CL, Shields JA. Recent developments in the management of choroidal melanoma. Curr Opin Ophthalmol. 2004;15 (3):244-51. https://doi.org/10.1097/01.icu.0000120713.35941.e4
  • 19. Lee YTN. Malignant melanoma: pattern of metastasis. CA: a cancer journal for clinicians. 1980;30 (3):137-42. https://doi.org/10.3322/canjclin.30.3.137
  • 20. Piotrowski W, Brock M, Klinger M. CNS Metastases Neurosurgery in the Aged: Proceedings of the 34th Annual Meeting of the Deutsche Gesellschaft für Neurochirurgie, Mannheim, April 27-30, 1983: Springer Science & Business Media; 2012. https://doi.org/10.1007/978-3-642-69360-1
  • 21. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10 (5):1670-7. https://doi.org/10.1158/1078-0432.CCR-1103-3
  • 22. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncology. 1999;17 (9):2745. https://doi.org/10.1200/JCO.1999.17.9.2745
  • 23. Avril MF, Aamdal S, Grob J, Hauschild A, Mohr P, Bonerandi J, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncology. 2004;22 (6):1118-25. https://doi.org/10.1200/JCO.2004.04.165
  • 24. Glover D, Glick JH, Weiler C, Fox K, Guerry D. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncology. 1987;5 (4):574-8. https://doi.org/10.1200/JCO.1987.5.4.574
  • 25. Quagliana JM, Stephens R, Baker L, Costanzi J. Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study. J Clin Oncology. 1984;2 (4):316-9. https://doi.org/10.1200/JCO.1984.2.4.316
  • 26. Aamdal S, Wolff I, Kaplan S, Paridaens R, Kerger J, Schachter J, et al. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer. 1994;30 (8):1061-4. https://doi.org/10.1016/0959-8049(94)90456-1
  • 27. Dhomen N, Marais R. New insight into BRAF mutations in cancer. Current opinion in genetics & development. 2007;17 (1):31-9. https://doi.org/10.1016/j.gde.2006.12.005
  • 28. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364 (26):2507-16. https://doi.org/10.1056/NEJMoa1103782
  • 29. [Cancer Statistics Turkey, 2008] (in Turkish). Republic of Turkey Ministry of Health, Department of Cancer. Available at: https://hsgm.saglik.gov.tr/depo/birimler/kanser-db/istatistik/2009kanseraporu-1.pdf (Access Date: March 01, 2015)
  • 30. Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int. J. Cancer. 1997;73 (2):198-203. https://doi.org/10.1002/(SICI)1097-0215(19971009)73:2<198::AID-IJC6>3.0.CO;2-R
  • 31. Nelemans PJ, Groenendal H, Kiemeney L, Rampen F, Ruiter DJ, Verbeek A. Effect of intermittent exposure to sunlight on melanoma risk among indoor workers and sun-sensitive individuals. Environmental health perspectives. 1993;101 (3):252. https://doi.org/10.1289/ehp.93101252
  • 32. The International Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: a systematic review. Int. J. Cance. 2007;120 (5):1116-22. https://doi.org/10.1002/ijc.22453
Toplam 32 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Klinik Tıp Bilimleri
Bölüm Araştırma Makalesi (Original Article)
Yazarlar

Mustafa Solak 0000-0001-7939-7781

Saadettin Kılıçkap 0000-0003-1637-7390

İsmail Celık 0000-0003-1182-3865

Yayımlanma Tarihi 5 Mayıs 2021
Gönderilme Tarihi 17 Nisan 2020
Kabul Tarihi 26 Şubat 2021
Yayımlandığı Sayı Yıl 2021Cilt: 6 Sayı: 2

Kaynak Göster

APA Solak, M., Kılıçkap, S., & Celık, İ. (2021). Retrospective evaluation of malignant melanoma patients: A single-center experience. Family Practice and Palliative Care, 6(2), 98-104. https://doi.org/10.22391/fppc.717911
AMA Solak M, Kılıçkap S, Celık İ. Retrospective evaluation of malignant melanoma patients: A single-center experience. Fam Pract Palliat Care. Mayıs 2021;6(2):98-104. doi:10.22391/fppc.717911
Chicago Solak, Mustafa, Saadettin Kılıçkap, ve İsmail Celık. “Retrospective Evaluation of Malignant Melanoma Patients: A Single-Center Experience”. Family Practice and Palliative Care 6, sy. 2 (Mayıs 2021): 98-104. https://doi.org/10.22391/fppc.717911.
EndNote Solak M, Kılıçkap S, Celık İ (01 Mayıs 2021) Retrospective evaluation of malignant melanoma patients: A single-center experience. Family Practice and Palliative Care 6 2 98–104.
IEEE M. Solak, S. Kılıçkap, ve İ. Celık, “Retrospective evaluation of malignant melanoma patients: A single-center experience”, Fam Pract Palliat Care, c. 6, sy. 2, ss. 98–104, 2021, doi: 10.22391/fppc.717911.
ISNAD Solak, Mustafa vd. “Retrospective Evaluation of Malignant Melanoma Patients: A Single-Center Experience”. Family Practice and Palliative Care 6/2 (Mayıs 2021), 98-104. https://doi.org/10.22391/fppc.717911.
JAMA Solak M, Kılıçkap S, Celık İ. Retrospective evaluation of malignant melanoma patients: A single-center experience. Fam Pract Palliat Care. 2021;6:98–104.
MLA Solak, Mustafa vd. “Retrospective Evaluation of Malignant Melanoma Patients: A Single-Center Experience”. Family Practice and Palliative Care, c. 6, sy. 2, 2021, ss. 98-104, doi:10.22391/fppc.717911.
Vancouver Solak M, Kılıçkap S, Celık İ. Retrospective evaluation of malignant melanoma patients: A single-center experience. Fam Pract Palliat Care. 2021;6(2):98-104.

Family Practice and Palliative Care      ISSN 2458-8865       E-ISSN 2459-1505